Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/12/2025 | $46.00 | Mkt Outperform | Citizens JMP |
| 1/27/2025 | Overweight | Cantor Fitzgerald | |
| 12/13/2024 | $34.00 | Outperform | RBC Capital Mkts |
| 11/8/2024 | $33.00 | Buy | Guggenheim |
| 8/14/2024 | $24.00 | Neutral → Buy | H.C. Wainwright |
| 12/3/2021 | $6.00 | Buy | H.C. Wainwright |
| 9/22/2021 | $9.00 → $8.00 | Buy | Aegis Capital |
| 9/22/2021 | $6.25 | Buy → Strong Buy | WBB Securities |
Citizens JMP initiated coverage of Cidara Therapeutics with a rating of Mkt Outperform and set a new price target of $46.00
Cantor Fitzgerald resumed coverage of Cidara Therapeutics with a rating of Overweight
RBC Capital Mkts initiated coverage of Cidara Therapeutics with a rating of Outperform and set a new price target of $34.00
4 - Cidara Therapeutics, Inc. (0001610618) (Issuer)
- $240 million private placement financing led by RA Capital Management with significant participation by Bain Capital Life Sciences as well as BVF Partners and Canaan Partners to fund Phase 2b clinical trial - CD388, which is active against all strains of influenza A and B, is being developed for pre-exposure prophylactic treatment - Company to host business strategy update conference call and webcast today at 4:30 PM ET SAN DIEGO, April 24, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve
Submitted NDA for rezafungin for candidemia and invasive candidiasis to the U.S. FDA on July 22, 2022, with an anticipated PDUFA target action date in the first quarter of 2023, if accepted for review following application validationMelinta acquires exclusive rights to commercialize rezafungin in the U.S.Cidara to receive up to $460 million, with an upfront cash payment of $30 million, $60 million in regulatory milestones, and up to $370 million in commercial milestones, plus tiered low double digits to mid-teens royalties on net salesCidara to focus on advancing Cloudbreak DFC platform in oncology and viral infections SAN DIEGO, July 27, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc
Trial met FDA and EMA-pre-specified primary endpoints versus daily standard of care Data to support global regulatory filings in mid-2022 Cidara to host investor conference call today, December 14th, at 8:30 a.m. EST to provide further details on the data SAN DIEGO and CAMBRIDGE, United Kingdom, Dec. 14, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX) and Mundipharma today announced positive topline data from the pivotal ReSTORE Phase 3 clinical trial evaluating the efficacy and safety of its once-weekly antifungal candidate rezafungin as a potential first-line treatment for candidemia and invasive candidiasis. Rezafungin met the primary endpoint for the U.S. Food and
4 - Cidara Therapeutics, Inc. (0001610618) (Issuer)
4 - Cidara Therapeutics, Inc. (0001610618) (Issuer)
4 - Cidara Therapeutics, Inc. (0001610618) (Issuer)
Completed enrollment of 5,000 subject Phase 2b NAVIGATE trialSevere flu season enables potential mid-year assessment of efficacyClosed $105.0 million financing with new and existing investorsSignificantly expanded equity research coverage SAN DIEGO, March 06, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies, today reported financial results for the fourth quarter and full year ended December 31, 2024 and provided recent business updates. "2024 was a transformational year for Cidara as we reacquired rights to the CD388 program
SAN DIEGO, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced that Frank Karbe, MBA, has been appointed Chief Financial Officer (CFO), effective February 24, 2025. Mr. Karbe will succeed Preetam Shah, Ph.D., MBA, who is departing to pursue other professional opportunities. Dr. Shah will serve as a consultant to the Company. "We are pleased to welcome Frank to the team as we advance our long-acting influenza antiviral drug CD388 through the e
SAN DIEGO, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced that Jeffrey Stein, Ph.D., President and Chief Executive Officer, will participate in the Guggenheim Securities SMID Cap Biotech Conference. Details are as follows: Event: Guggenheim Securities SMID Cap Biotech ConferenceDate: Wednesday, February 5, 2025Time: 1:30 PM ET Format: Fireside chat Webcast: https://wsw.com/webcast/guggen2/cdtx/2014749 A replay of the presentation will
Completed enrollment of 5,000 subject Phase 2b NAVIGATE trialSevere flu season enables potential mid-year assessment of efficacyClosed $105.0 million financing with new and existing investorsSignificantly expanded equity research coverage SAN DIEGO, March 06, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies, today reported financial results for the fourth quarter and full year ended December 31, 2024 and provided recent business updates. "2024 was a transformational year for Cidara as we reacquired rights to the CD388 program
SAN DIEGO, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced that Frank Karbe, MBA, has been appointed Chief Financial Officer (CFO), effective February 24, 2025. Mr. Karbe will succeed Preetam Shah, Ph.D., MBA, who is departing to pursue other professional opportunities. Dr. Shah will serve as a consultant to the Company. "We are pleased to welcome Frank to the team as we advance our long-acting influenza antiviral drug CD388 through the e
SAN DIEGO, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced the appointment of Rick Bright, Ph.D., Philip Krause, M.D., Mario Barro, Ph.D., and Frederick G. Hayden, M.D., FACP to its Scientific Advisory Board (SAB). "We are honored that these four esteemed physicians and scientists have agreed to join our Scientific Advisory Board," said Jeffrey Stein, Ph.D., president and chief executive officer of Cidara. "They have already provided i
SC 13G - Cidara Therapeutics, Inc. (0001610618) (Subject)
SC 13G - Cidara Therapeutics, Inc. (0001610618) (Subject)
SC 13G - Cidara Therapeutics, Inc. (0001610618) (Subject)
S-8 - Cidara Therapeutics, Inc. (0001610618) (Filer)
8-K - Cidara Therapeutics, Inc. (0001610618) (Filer)
10-K - Cidara Therapeutics, Inc. (0001610618) (Filer)